A High-Affinity, Dimeric Inhibitor of Psd-95 Bivalently Interacts with Pdz1-2 and Protects Against Ischemic Brain Damage.
Bach, A., Clausen, B.H., Moller, M., Vestergaard, B., Chi, C.N., Round, A., Sorensen, P.L., Nissen, K.B., Kastrup, J.S., Gajhede, M., Jemth, P., Kristensen, A.S., Lundstrom, P., Lambertsen, K.L., Stromgaard, K.(2012) Proc Natl Acad Sci U S A 109: 3317
- PubMed: 22343531 
- DOI: https://doi.org/10.1073/pnas.1113761109
- Primary Citation of Related Structures:  
3ZRT - PubMed Abstract: 
Inhibition of the ternary protein complex of the synaptic scaffolding protein postsynaptic density protein-95 (PSD-95), neuronal nitric oxide synthase (nNOS), and the N-methyl-D-aspartate (NMDA) receptor is a potential strategy for treating ischemic brain damage, but high-affinity inhibitors are lacking. Here we report the design and synthesis of a novel dimeric inhibitor, Tat-NPEG4(IETDV)(2) (Tat-N-dimer), which binds the tandem PDZ1-2 domain of PSD-95 with an unprecedented high affinity of 4.6 nM, and displays extensive protease-resistance as evaluated in vitro by stability-measurements in human blood plasma. X-ray crystallography, NMR, and small-angle X-ray scattering (SAXS) deduced a true bivalent interaction between dimeric inhibitor and PDZ1-2, and also provided a dynamic model of the conformational changes of PDZ1-2 induced by the dimeric inhibitor. A single intravenous injection of Tat-N-dimer (3 nmol/g) to mice subjected to focal cerebral ischemia reduces infarct volume with 40% and restores motor functions. Thus, Tat-N-dimer is a highly efficacious neuroprotective agent with therapeutic potential in stroke.
Organizational Affiliation: 
Department of Medicinal Chemistry, University of Copenhagen, DK-2100 Copenhagen, Denmark. anba@farma.ku.dk